Literature DB >> 8787446

Staging non-small cell lung cancer by whole-body positron emission tomographic imaging.

P E Valk1, T R Pounds, D M Hopkins, M K Haseman, G A Hofer, H B Greiss, R W Myers, C L Lutrin.   

Abstract

BACKGROUND: A need exists for an accurate, noninvasive means of staging non-small cell lung cancer.
METHODS: A prospective evaluation of regional and whole-body positron emission tomography (PET) imaging for staging lung cancer was carried out in 99 patients. Mediastinal PET and computed tomography findings were compared with results of surgical staging in 76 patients. Those PET and computed tomography findings that indicated possible distant metastasis were compared with biopsy results and the results of clinical and imaging follow-up.
RESULTS: Sensitivity and specificity for the diagnosis of N2 disease were 83% and 94% for PET and 63% and 73% for computed tomography, respectively. Positron emission tomography showed previously unsuspected distant metastasis in 11 patients (11%), with no demonstrated false-positive results. Normal PET findings were obtained at distant sites of computed tomography abnormality in 19 patients (19%). Clinical and imaging follow-up in 14 of these patients showed no evidence of metastasis. In 1 case, the PET result proved to be falsely negative.
CONCLUSIONS: Imaging with PET was more accurate than computed tomography for diagnosis of mediastinal and distant metastasis. Detection of unsuspected metastatic disease by PET may permit reduction in the number of thoracotomies performed for nonresectable disease.

Entities:  

Mesh:

Year:  1995        PMID: 8787446     DOI: 10.1016/0003-4975(95)00752-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  27 in total

Review 1.  Recent advances: Respiratory medicine.

Authors:  H A Kerstjens; H J Groen; W van Der Bij
Journal:  BMJ       Date:  2001-12-08

Review 2.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 3.  Positron emission tomography (PET) in the evaluation of patients with cancer.

Authors:  H A Godwin; J H Zuger
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

4.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

5.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

6.  Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer.

Authors:  Haruhiko Nakamura; Masahiko Taguchi; Hajime Kitamura; Junichi Nishikawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-08-13

7.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

Review 8.  Decision making in patients with pulmonary nodules.

Authors:  David E Ost; Michael K Gould
Journal:  Am J Respir Crit Care Med       Date:  2011-10-06       Impact factor: 21.405

Review 9.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

Review 10.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.